NCT04049734View on ClinicalTrials.gov

Oral Losartan in Prevention of Post-ERCP Paancreatitis

PHASE1CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

January 31, 2017

Study Completion Date

March 31, 2017

Conditions
Post-ERCP Acute Pancreatitis
Interventions
DRUG

oral losatan

50 mg of oral losartan one hour before the ERCP once

All Listed Sponsors
lead

Ain Shams University

OTHER

NCT04049734 - Oral Losartan in Prevention of Post-ERCP Paancreatitis | Biotech Hunter | Biotech Hunter